Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

41.69 +0.95 (+2.33%)
Official Closing Price Updated: 4:15 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
News headline image
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer ↗
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
News headline image
A Peek Into The Markets: US Stock Futures Edge Higher; Crude Oil Up 0.5% ↗
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the three major averages recorded losses last week. Investors are awaiting earnings... 
Via Benzinga
News headline image
Early Monday Report - More Moves Out Of China ↗
Before it even turned Monday in the West, China insurers are feeling the heat. 
Via Talk Markets
News headline image
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
From Exelixis, Inc.
Via Business Wire
News headline image
The Sunday File for Nov. 21 ↗
Good news and bad - making up for the short week by getting a Sunday start. 
Via Talk Markets
News headline image
Analyst Ratings For Exelixis ↗
Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ: 
Via Benzinga
News headline image
Post-Fed Thursday ↗
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today. 
Via Talk Markets
News headline image
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
News headline image
7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now ↗
These cheap stocks are trading at highly attractive prices and have the potential to break through this year. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug... 
Via Benzinga
News headline image
Exelixis Elects Jacqueline Wright to Its Board of Directors
From Exelixis, Inc.
Via Business Wire
News headline image
Uncertain Times ↗
The UK inflation rate last month was 5.1%, not a good omen. 
Via Talk Markets
News headline image
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
3 No-Brainer Biotech Stocks to Buy in November ↗
Here are three Motley Fool contributors' top picks. 
Via The Motley Fool
News headline image
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
From Exelixis, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
News headline image
Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript ↗
EXEL earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Exelixis: Q3 Earnings Insights ↗
Exelixis (NASDAQ:EXEL) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Exelixis... 
Via Benzinga
News headline image
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Earnings Perspective: Return On Capital Employed ↗
According to Benzinga Pro, during Q2, Exelixis (NASDAQ:EXEL) earned $123.01 million, a 2770.02% increase from the preceding quarter. Exelixis also posted a total of $385.18... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
News headline image
Here's My Top Value Stock To Buy Right Now ↗
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications. 
Via Talk Markets
News headline image
Down 76%: Is Cortexyme Stock a Bargain? ↗
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial. 
Via The Motley Fool
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.